品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

Medchemexpress/D-Luciferin(Synonyms: D-(-)-Luciferin; Firefly luciferin)/HY-12591A/10mg

价格
¥1100.00
货号:HY-12591A-10mM*1mLinDMSO
浏览量:127
品牌:MCE
服务
全国联保
正品保证
正规发票
签订合同
商品描述
D-luciferin is the natural substrate of luciferases that catalyze the production of light in bioluminescent insects.
Description

D-luciferin is the natural substrate of luciferases that catalyze the production of light in bioluminescent insects.

In Vitro

D-luciferin is the natural substrate of the enzyme luciferase (Luc), that catalyzes the production of the typical yellowgreen light of fireflies.The present review covers the synthesis of D-luciferin and derivatives or analogues that are substrates or inhibitors of the luciferase from the American firefly Photinus pyralis, the enzyme more frequently used in techniques of in vitro and optical imaging[1].

In Vivo

Bioluminescence imaging (BLI) using the firefly luciferase (Fluc) as a reporter gene and D-luciferin as a substrate is currently the most widely employed technique. The total signal intensity is plotted against the time after D-luciferin injection to generate a time-intensity curve. In addition to the peak signal, the signals at fixed time points (5, 10, 15, and 20 min) after D-luciferin injection are determined as alternatives to the peak signal. The signal in a given time-intensity curve is normalized for the peak signal in the curve to represent the pattern of temporal changes after D-luciferin injection[2].

References
  • [1]. Giuseppe Meroni, et al. D-Luciferin, derivatives and analogues: synthesis and in vitro/in vivo luciferase-catalyzed bioluminescent activity. ARKIVOC 2009 (i) 265-288.

    [2]. Inoue Y, et al. Timing of imaging after d-luciferin injection affects the longitudinal assessment of tumor growthusing in vivo bioluminescence imaging. Int J Biomed Imaging. 2010;2010:471408.

Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.5674 mL 17.8368 mL 35.6735 mL
5 mM 0.7135 mL 3.5674 mL 7.1347 mL
10 mM 0.3567 mL 1.7837 mL 3.5674 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration
[2]

D-luciferin is prepared in phosphate-buffered saline (Mice)[2].

Mice[2]
In vivo BLI is performed using a cooled charge-coupled device camera system (IVIS Imaging System 100) 3, 5, 7, 10, 12, 14, 19, 21, 24, and 28 days after the inoculation of HCT116-Luc cells. Mice are injected with 75 mg/kg D-luciferin in 100 L of phosphate-buffered saline subcutaneously near the scapula and were placed in the light-tight chamber of the imaging system under isoflurane anesthesia. Beginning 5 min after injection, dorsal luminescent images with an exposure time of 1 s are acquired sequentially at a rate of one image per min until 20 min after D-luciferin injection. Data acquisition is continued until 40 min postinjection on days 3 or 5 and until 25 min on day 7, because of the prolonged time course of light emission. Binning is 4 and the field of view is 15 cm.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
  • [1]. Giuseppe Meroni, et al. D-Luciferin, derivatives and analogues: synthesis and in vitro/in vivo luciferase-catalyzed bioluminescent activity. ARKIVOC 2009 (i) 265-288.

    [2]. Inoue Y, et al. Timing of imaging after d-luciferin injection affects the longitudinal assessment of tumor growthusing in vivo bioluminescence imaging. Int J Biomed Imaging. 2010;2010:471408.

Molecular Weight

280.32

Formula

C₁₁H₈N₂O₃S₂

CAS No.

2591-17-5

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 14.7 mg/mL

* "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity: 98.11%

Data Sheet (129 KB) SDS (389 KB)

COA (93 KB) HNMR (549 KB) LCMS (299 KB)

Handling Instructions (1252 KB)
  • [1]. Giuseppe Meroni, et al. D-Luciferin, derivatives and analogues: synthesis and in vitro/in vivo luciferase-catalyzed bioluminescent activity. ARKIVOC 2009 (i) 265-288.

    [2]. Inoue Y, et al. Timing of imaging after d-luciferin injection affects the longitudinal assessment of tumor growthusing in vivo bioluminescence imaging. Int J Biomed Imaging. 2010;2010:471408.

他替瑞林口服促甲状腺素释放激素他替瑞林CAS号:103300-74-9英文名称:Taltirelin英文同义词:TA0910;Taltirelin;Taltireline;Ceredist,TA-0910;TaltirelinAcetate;TA-0910,taltirelin;TaltirelininterMediate;TALTIRELININTERMEDIATES;TaltirelinAcetate,TA-0910;L-Prolinamide,(4S)-hexahydro-1-methyl-中文名称:他替瑞林中文同义词:他替瑞林;醋酸他替瑞林;1-METHYL-4,5-DIHYDROOROTYL-HIS-PRO-NH2;(4S)-N-[(2S)-1-[(2S)-2-氨基甲酰基吡咯烷-1-基]-3-(3H-咪唑-4-基)-1-氧代丙-2-基]-1-甲基-2,6-二氧代-1,3-二氮杂己环-4-甲酰胺CBNumber:CB31177191分子式:C17H23N7O5分子量:405.41MOLFile:103300-74-9.mol化学性质安全信息用途供应商86化学性质安全信息用途供应商86他替瑞林化学性质熔点:72-75°比旋光度:25D-13.6°(c=1inwater)密度:1.447±0.06g/cm3(Predicted)储存条件:Storeat+4°C酸度系数(pKa):9.32±0.40(Predicted)安全信息他替瑞林性质、用途与生产工艺口服促甲状腺素释Chemicalbook放激素他替瑞林是一种垂体激素释放兴奋药,由日本田边三菱制药株式会社研制成功,商品名Taltirelin,属于化药新药3.1类,目前临床用于改善脊髓小脑变性患者的运动失调最为有效的药物。他替瑞林(Taltirelin)是世界上第一个批准的口服促甲状腺素释放激素(TRH),除具有内分泌作用外,还可发挥一定的中枢神经系统(CNS)作用,包括提高运动活性,拮抗利舍平诱导的体温降低,以及拮抗戊巴比妥诱导的睡眠。该品种由日本田边三菱制药株式会社开发,2000年9月首次在日本上市,用于改善脊髓小脑变性病人的共济失调。脊髓小脑共济失调(SCAs)旧称常染色体显性共济失调,是一组以共济失调、辨距不良为主要临床表现的中枢神经系统慢性变性疾病。2000年9月前,促甲状腺素释放激素(TRH)注射液是唯一用于治疗该类疾病的药物。他替瑞林是TRH的结构修饰改造药物,药理学研究显示本品经由脑TRH受体对CNS产生强而持久的多重作用。本品对CNS的兴奋作用比TRH强10~100倍,作用持续时间比TRH长约8倍。本品对TRH受体的亲和力约为TRH的1/11,因而本品的内分泌作用比TRH弱,但本品在体内比TRH稳定。另外本品对促甲状腺素(TSH)释放的作用为TRH的1/6-1/11,TSH释放是由一个包括甲状腺激素的强负反馈系统调节的,对中枢神经系统具有较强的作用,但同时其激素样作用较小,因此副作用较少。不良反应主要是消化系统反应,包括呕吐、恶心和胃不适。所有的不良反应均为轻中度,在治疗期间及(或)停药后消失。